Company intelligence / Profile preview

PhagePro

Boston, Massachusetts, United Statesphageproinc.com ↗

Ownership: Private
Employees: ~5
Development stage: Preclinical

Overview

PhagePro’s lead product, ProphaLytic-Vc, has demonstrated promise in preclinical studies as an oral bacteriophage preparation targeting epidemic cholera strains. The company aims to prevent household and community transmission of cholera with a rapidly acting prophylactic treatment. Clinical trials are being prepared but have not yet commenced as of the latest available information.

Therapeutic areas: Infectious Diseases
Modalities: Bacteriophage-based therapeutics (phages)
Industry: Biotech

Drug pipeline

1 asset

ProphaLytic-Vc

Preclinical

Partnerships

Collaborations with external partners for formulation optimization and manufacturing CROs mentioned; specific partner names not disclosed.

Beyond the preview

Go deeper on PhagePro.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PhagePro.

Explore the full profile